BofA cuts Vertex target to USD 667: Vertex stock after-hours at EUR 434.98
Published on 10/13/2026 at 23:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget revision and next results
- BofA Securities lowered its Vertex price target to USD 667 on October 13, 2026.
- Vertex Pharma traded after-hours at EUR 434.98 at 10:58 p.m. CEST at Lang & Schwarz on October 13, 2026.
- Vertex is scheduled to report third-quarter results on November 2, 2026.
Investing.com reported on October 13, 2026, that BofA Securities lowered its price target for Vertex Pharmaceuticals to USD 667 from USD 672 while maintaining a Buy rating. The report said BofA's updated model projected Trikafta revenue of USD 2.42 billion, compared with USD 2.54 billion in Wall Street consensus estimates.
Vertex Pharma traded after-hours at EUR 434.98 at 10:58 p.m. CEST on October 13, 2026, at Lang & Schwarz. The bid was EUR 432.30 and the ask was EUR 437.65. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Daily balance
MarketsFN listed the Nasdaq Composite at 27,244.91 with a 0.00 percent change in its October 13, 2026 market update. The index is the benchmark for Vertex's Nasdaq home market, while the Lang & Schwarz quote showed a bid-ask range from EUR 432.30 to EUR 437.65.
Tomorrow: Vertex is scheduled to report third-quarter financial results on November 2, 2026, according to Investing.com.
Market context: Market report Nasdaq Composite.
